Small Molecules

19 Jan 2019 TYME’s Novel Metabolic-Based Cancer Therapy, SM-88, Improves Survival in Phase II Study of Patients with Advanced Pancreatic Cancer
19 Jan 2019 Kura Oncology Reports Clinical Activity of Tipifarnib in Subsets of Pancreatic Cancer Associated with High CXCL12 Expression
19 Jan 2019 AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Metastatic Pancreatic Cancer
18 Jan 2019 Promentis Pharmaceuticals Announces Commencement of Phase 2 Studies for SXC-2023 Targeting Novel Glutamatergic Mechanism
18 Jan 2019 AgeneBio Announces First Patient Enrollment in the Phase 3 Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease
17 Jan 2019 Janssen announces European Commission approval of ERLEADA® (apalutamide) for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease
17 Jan 2019 Aeterna Zentaris Receives European Marketing Clearance for Macimorelin
17 Jan 2019 Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor
17 Jan 2019 Aptinyx Reports Top-line Results from Phase 2 Clinical Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
15 Jan 2019 Tolero Pharmaceuticals Announces First Patient Dosed with Investigational Agent TP-1287 in Phase 1 Study in Patients with Advanced Solid Tumors
15 Jan 2019 BeiGene Receives U.S. FDA Breakthrough Therapy Designation for Zanubrutinib in Mantle Cell Lymphoma
15 Jan 2019 Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma
15 Jan 2019 US FDA Accepts Regulatory Submissions for Review of Tafamidis to Treat Transthyretin Amyloid Cardiomyopathy
15 Jan 2019 Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment
15 Jan 2019 New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States
15 Jan 2019 Aslan Pharmaceuticals announces study results from phase 2 study of varlitinib in first-line gastric cancer
12 Jan 2019 ChemomAb Doses First Patient in Phase 1b Clinical trial of CM-101 in Patients With Non-Alcoholic Fatty Liver Disease
12 Jan 2019 Corvus Announces Presentation of Preclinical Data on CPI-818, a First-in-class Covalent Inhibitor of ITK Targeting T-Cell Lymphomas
09 Jan 2019 Novus Therapeutics Doses First Patient with Acute Otitis Media in Phase 1 Study of OP0201
09 Jan 2019 Rafael Pharmaceuticals Announces Initiation of Patient Enrollment for Phase II Clinical Trial of CPI-613 for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia
09 Jan 2019 Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for ALS
09 Jan 2019 Basilea reports positive interim results from registrational phase 2 study with oncology drug candidate derazantinib in intrahepatic cholangiocarcinoma (iCCA)
09 Jan 2019 UroGen Pharma Announces Positive Results of UGN-101 from Pivotal Phase 3 OLYMPUS Trial for the Non-Surgical Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC)
08 Jan 2019 Spero Therapeutics Signs License Agreement with Everest Medicines to Develop, Manufacture and Commercialize SPR206 in Asia, with Option for SPR741 Rights, and Initiates SPR206 Phase 1 Clinical Trial
08 Jan 2019 Forbius Announces the First Patient Dosed in a Phase 1 Oncology Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up